TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02264340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation technique Autogenic Training
Description: Autogenic Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined treatment Autogenic Training + Cervical exercises and postural correction
Description: Autogenic Training + Cervical exercises and postural correction
Study: NCT00524901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alpha
Description: A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
Study: NCT03264573

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell
Description: after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell
Description: after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MSCs
Description: manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MSCs
Description: manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells
Study: NCT01826006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Thrombus Aspiration
Study: NCT04632134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation (tVNS)
Description: Transcutaneous vagal nerve stimulation (tVNS) will be performed using a noninvasive battery powered Transcutaneous Electrical Nerve Stimulation device (Nemos ©; Cerbomed, Germany). Electrical stimulation will be delivered by external electrodes through the skin surface at the conca of right external ear. Electrical current will be applied continuously with a pulse width of 200 μs and pulse frequency of 25 Hz. Stimulation amplitude will be adjusted between 0.1-6 mA, to a maximal amplitude level without causing patient discomfort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tVNS electrodes will be positioned in the right ear of the POTS patients without delivering stimulus (Sham)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home daily transcutaneous vagal nerve stimulation
Description: The home stimulation will consist of 4 hours of stimulation by the tVNS device organized as a 4 sessions of 1 hour. The home stimulation will last for 14 consecutive days.
Study: NCT04260594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbidol
Description: Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days
Study: NCT03615950

Intervention type: DIAGNOSTIC_TEST
Intervention: Bone Mineral Density (DEXA) scan
Description: Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bone Mineral Density (DEXA) scan
Description: Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
Study: NCT04260594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: basic treatment
Description: basic treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: basic treatment
Description: basic treatment
Study: NCT04156438

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low tidal volume ventilation
Description: Conventional ventilation strategy for patient with ARDS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway pressure release ventilation
Description: Experimental ventilation protocol for patients with ARDS
Study: NCT04380662

Intervention type: OTHER
Intervention: Risk factors
Description: The studied potential risk factors will be the following:~* Socio-demographic: age, sex, place of residence, CSP and income.~* Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc.~* Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain...~* Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA...)
Study: NCT03866811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dr. Erica
Description: The 10 week texting intervention contains the follow characteristics to increase engagement: (1) Dr. ERICA (Emergency Room Interventions to Improve the Care of Adolescents): The persona and brand of the intervention is Dr. Erica, a relatable, empathetic, straightforward and reliable female doctor; (2) Personalization: Information collected at baseline will be incorporated into each individualized program; (3) Interactivity: The majority of text message algorithms contain 3-4 two-way automated messaging conversations. (4) Feedback loops: The investigators will collect feedback from participants to prompt action; (5) Visual stimuli: Texts include emojis, memes, and other visual stimuli, similar to current teen texting behaviors; (6) Social media: The investigators designed sexual health comic strips posted as an Instagram story; (7) Links and role modeling: Texts contain links to testimonials, influencers, and evidence-based websites.
Study: NCT03615950

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D Measurement
Description: Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
Study: NCT01445015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management program
Description: 10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peer viewed movies
Description: PG rated movies to be viewed over 10 sessions in peer setting
Study: NCT02554084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Digital images of tear film

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: Digital images of tear film
Study: NCT02048527

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global
Description: Single medium for the culture of embryos from Day1 to Day 5

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Origio
Description: Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
Study: NCT02267616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etonogestrel Implant
Description: Subdermal arm implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel Implant
Description: Subdermal arm implant
Study: NCT01950052

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet group 800 Kcal diet
Description: Pre-operative liver shrinking diet of 800 kcal is administered for 4 weeks
Study: NCT01073176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAMS (Training Attention Executive and Motor Skills)
Description: Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
Study: NCT04281121

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3 fatty acids
Description: : Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3 fatty acids
Description: : Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals
Study: NCT01352871

Intervention type: BEHAVIORAL
Intervention: Concentration / meditation
Description: from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response

Intervention type: DRUG
Intervention: lipopolysaccharide
Description: lipopolysaccharide 2ng/kg intravenously
Study: NCT03710681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
Study: NCT02401724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Training
Study: NCT05573425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene gel 0.1%
Description: Tazarotene gel 0.1% applied daily on Acne Scars.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling
Description: Microneedling via dermaroller device performed on Acne Scars monthly.
Study: NCT04381117

Intervention type: DRUG
Intervention: Previously Treated with EN3835
Description: No treatment to be administered - Observational only
Study: NCT01553708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor with silver sulfadiazine cream
Description: Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver zinc sulfadiazine cream
Description: Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
Study: NCT04859959

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gallium-68 Pentixafor PET/CT
Description: Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.
Study: NCT01813786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser with handpiece 2
Description: Focusing energy on skin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser with handpiece 1
Description: focusing energy at skin surface

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser with handpiece 3
Description: Focusing energy on skin
Study: NCT00882804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemin infusion
Description: Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in \~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: 25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
Study: NCT01367626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: 2.5 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: 2.5 mg tablet
Study: NCT04554563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability training
Description: 20 sessions of specific core stability exercise with no external loading.
Study: NCT03857425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridum Butyricum Capsule
Description: Clostridum Butyricum Capsule 3\*420mg,twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Coagulans Tablets
Description: Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets
Description: Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
Study: NCT03905928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Containing ECIG with tobacco flavor
Description: Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a tobacco flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Containing ECIG with Strawberry Vanilla Flavor
Description: Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a strawberry vanilla flavor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ECIG with Tobacco Flavor
Description: Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a tobacco flavor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ECIG with Strawberry Vanilla Flavor
Description: Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a strawberry vanilla flavor.
Study: NCT03605108

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: • Probiotic fomula per capsule:~* 2 Billion CFUs~* HU36 - 30 mg~* HU58 - 20 mg~* Bacillus clausii -25 mg~* Bacillus coagulans 10B - 35 mg~* Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour only
Study: NCT00302068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Aerobic Exercise
Description: Supervised aerobic exercise, three times per week, for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline (Zoloft), daily, for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill.
Description: Placebo pill, daily, for 16 weeks.
Study: NCT00728273

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: worm treatment and multiple micronutrient fortified biscuits
Description: A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: worm treatment and multiple micronutrient fortified biscuits
Description: A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin.
Study: NCT02764593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Anti-cancer alkylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Epidermal Growth Factor Receptor (EGFR) antagonist

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: High-precision radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: High-precision radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: High-precision radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: High-precision radiotherapy
Study: NCT02806882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: 600mg IV infusion
Study: NCT00640354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated external defibrillator
Description: Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual defibrillator
Description: Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
Study: NCT01589211

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: Brief advice of about 10 min accompanied by self-help material

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compact cessation course
Description: Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard cessation course
Description: Cessation course over 6 dates. Group setting.
Study: NCT02846142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ethinyl estradiol and levonorgestrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol and levonorgestrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinyl estradiol and levonorgestrel
Study: NCT00720629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visilizumab
Description: 3 mg/m\^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg/m\^2 intravenously (IV) on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithymocyte globulin (ATG)
Description: 1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: 0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 15 mg/m\^2 IV on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
Study: NCT01474265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 0.5-2 mg per day, oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-2 tablets per day, oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette TX
Description: 10-15 mg per day, transdermal use (patches)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette TX
Description: 10-15 mg per day, transdermal use (patches)
Study: NCT00935116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery
Study: NCT02077140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDT-10013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care for pain